Cilostazol

CILOSTAZOL- cilostazol tablet
Bryant Ranch Prepack

Chemical Structure for Cilostazolfigure1figure 2

WARNING: CONTRAINDICATED IN HEART FAILURE PATIENTS

Cilostazol is contraindicated in patients with heart failure of any severity. Cilostazol and several of its

metabolites are inhibitors of phosphodiesterase III. Several drugs with this pharmacologic effect have caused

decreased survival compared to placebo in patients with class III-IV heart failure [see Contraindications (4)].

1 INDICATIONS AND USAGE

Cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance.

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosage

The recommended dosage of cilostazol tablets is 100 mg twice daily taken at least half an hour before or two hours after breakfast and dinner.


Patients may respond as early as 2 to 4 weeks after the initiation of therapy, but treatment for up to 12 weeks may be

needed before a beneficial effect is experienced. If symptoms are unimproved after 3 months, discontinue cilostazol tablets.

2.2 Dose Reduction With CYP3A4 and CYP2C19 Inhibitors

Reduce dose to 50 mg twice daily when coadministered with strong or moderate inhibitors of CYP3A4 (e.g.,

ketoconazole, itraconazole, erythromycin, and diltiazem) or inhibitors of CYP2C19 (e.g., ticlopidine, fluconazole, and

omeprazole) [see Drug Interactions ( 7.1)].

3 DOSAGE FORMS AND STRENGTHS

Cilostazol tablets USP are available as 50 mg pillow-shaped and 100 mg round, white to off-white, debossed tablets.

4 CONTRAINDICATIONS

Cilostazol tablets are contraindicated in patients with:

  • Heart failure of any severity: Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III-IV heart failure.
  • Hypersensitivity to cilostazol or any components of cilostazol tablets (e.g., anaphylaxis, angioedema)

5 WARNINGS AND PRECAUTIONS

5.1 Tachycardia

Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension. The increase in heart rate associated with

cilostazol is approximately 5 to 7 bpm. Patients with a history of ischemic heart disease may be at risk for exacerbations

of angina pectoris or myocardial infarction.

5.2 Left Ventricular Outflow Tract Obstruction

Left ventricular outflow tract obstruction has been reported in patients with sigmoid shaped interventricular septum. Monitor patients for the development of a new systolic murmur or cardiac symptoms after starting cilostazol.

5.3 Hematologic Adverse Reactions

Cases of thrombocytopenia or leukopenia progressing to agranulocytosis when cilostazol was not immediately discontinued have been reported. Agranulocytosis is reversible on discontinuation of cilostazol. Monitor platelets and

white blood cell counts periodically.

5.4 Hemostatic Disorders or Active Pathologic Bleeding

Cilostazol inhibits platelet aggregation in a reversible manner. Cilostazol has not been studied in patients with hemostatic

disorders or active pathologic bleeding. Avoid use of cilostazol in these patients.

6 ADVERSE REACTIONS

The following adverse reactions are discussed in greater detail in other sections of the labeling:

Patients with Heart Failure [see Boxed Warning]

Tachycardia [see Warnings and Precautions ( 5.1)]

Left Ventricular Outflow Tract Obstruction [see Warnings and Precautions ( 5.2)]

Hematologic Adverse Reactions [see Warnings and Precautions ( 5.3)]

Hemostatic Disorders or Active Pathologic Bleeding [see Warnings and Precautions ( 5.4)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials

of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed

in practice.

Adverse reactions were assessed in eight placebo-controlled clinical trials involving patients exposed to either 50 or 100 mg twice daily cilostazol (n = 1301) or placebo (n = 973), with a median treatment duration of 127 days for patients on cilostazol and 134 days for patients on placebo.

The most frequent adverse reaction resulting in discontinuation of therapy in more than 3% of patients treated with

cilostazol was headache [50 mg twice daily (1.3%), 100 mg twice daily (3.5%) and placebo (0.3%)]. Other frequent causes of discontinuation included palpitation and diarrhea, both 1.1% for cilostazol (all doses) versus 0.1% for placebo.

The most common adverse reactions, occurring in at least 2% of patients treated with cilostazol 50 or 100 mg twice daily,

are shown in Table 1.

Table 1: Most Common Adverse Reactions in Patients on Cilostazol 50 or 100 mg Twice Daily (Incidence at least 2% and Occurring More Frequently (≥ 2%) in the 100 mg Twice Daily Group than on Placebo)

Adverse Reactions

Placebo

(N = 973)

Cilostazol 50 mg twice daily

(N = 303)

Cilostazol 100 mg twice daily

(N = 998)

Headache

14%

27%

34%

Diarrhea

7%

12%

19%

Abnormal stools

4%

12%

15%

Palpitation

1%

5%

10%

Dizziness

6%

9%

10%

Pharyngitis

7%

7%

10%

Infection

8%

14%

10%

Peripheral edema

4%

9%

7%

Rhinitis

5%

12%

7%

Dyspepsia

4%

6%

6%

Abdominal pain

3%

4%

5%

Tachycardia

1%

4%

4%


Less frequent clinical significant adverse reactions (less than 2%) that were experienced by patients treated with cilostazol

50 mg twice daily or 100 mg twice daily in the eight controlled clinical trials and that occurred at a frequency in the

100 mg twice daily group greater than in the placebo group are listed below.

Body as a whole: fever, generalized edema, malaise

Cardiovascular: atrial fibrillation, heart failure, myocardial infarction, nodal arrhythmia, supraventricular tachycardia, ventricular extrasystoles, ventricular tachycardia

Digestive: anorexia, melena

Hematologic and Lymphatic: anemia

Metabolic and Nutritional: increased creatinine, hyperuricemia

Nervous: insomnia

Respiratory: epistaxis

Skin and Appendages: urticaria

Special Senses: conjunctivitis, retinal hemorrhage, tinnitus

Urogenital: urinary frequency

Page 1 of 4 1 2 3 4

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2021. All Rights Reserved.